7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked hypophosphataemia.

Burosumab is recommended, within its marketing authorisation, as an option for treating X‑linked hypophosphataemia in adults. Burosumab is only recommended if the company provides it according to the commercial arrangement.

Read NICE technology appraisal guidance